COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022-Reference-Cited by-同舟云学术

COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022

Published:2022-09-15 Issue:37 Volume:27 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Kislaya Irina¹²^ORCID,Machado Ausenda¹²,Magalhães Sarah³,Rodrigues Ana Paula²,Franco Rafael³,Leite Pedro Pinto⁴,Dias Carlos Matias¹²,Nunes Baltazar¹²

Affiliation:

1. Centro de Investigação em Saúde Pública, Escola Nacional de Saúde Pública, Universidade NOVA de Lisboa, Lisbon, Portugal

2. Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal

3. Serviços Partilhados do Ministério da Saúde, Lisbon, Portugal

4. Direção de Serviços de Informação e Análise, Direção-Geral da Saúde, Lisbon, Portugal

Abstract

We measured vaccine effectiveness (VE) against COVID-19-related severe outcomes in elderly people in Portugal between May and July 2022. In ≥ 80 year-olds, the second booster dose VE was 81% (95% CI: 75–85) and 82% (95% CI: 77–85), respectively, against COVID-19-related hospitalisation and death. The first booster dose VE was 63% (95% CI: 55–70) in ≥ 80 year-olds and 74% (95% CI: 66–80) in 60–79 year-olds against hospitalisation, and 63% (95% CI: 57–69) and 65% (95% CI: 54–74) against death.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference11 articles.

1. Direção-Geral da Saúde. Norma 02/2021 - Campanha de Vacinação Contra a COVID-19 - Dose de Reforço. [Standard 02/2021 - Vaccination campaign against COVID-19 – Booster dose]. Lisbon: Direção-Geral da Saúde; 2021. Portuguese. Available from: https://www.dgs.pt/normas-orientacoes-e-informacoes/normas-e-circulares-normativas/norma-n-0022021-de-30012021-pdf.aspx

2. European Centre for Disease Prevention and Control (ECDC), European Medicines Agency (EMA). COVID-19 : Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines. EMA/204784/2022. Stockholm: ECDC, Amsterdam: EMA; 2022. Available from: https://www.ema.europa.eu/en/documents/public-statement/covid-19-joint-statement-ecdc-ema-administration-fourth-dose-mrna-vaccines_.pdf

3. European Centre for Disease Prevention and Control (ECDC), European Medicines Agency (EMA). COVID-19 : Updated joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines. EMA/635144/2022. Stockholm: ECDC, Amsterdam: EMA;2022. Available from: https://www.ema.europa.eu/en/documents/public-statement/updated-joint-statement-ecdc-ema-additional-booster-doses-covid-19-vaccines_en.pdf

4. mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021.;Nunes;Euro Surveill,2021

5. National Institute of Health (INSA) Doutor Ricardo Jorge. Genetic diversity of the novel coronavirus SARS-CoV-2 (COVID-19) in Portugal. 23 August 2022 report. Lisbon: INSA; 2022. Available from: https://insaflu.insa.pt/covid19/relatorios/PORTUGAL_INSA_SARS_CoV_2_GENETIC_DIVERSITY_situation_report_2022-09-06.pdf

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study;The Lancet Respiratory Medicine;2024-09

2. The impact of the COVID-19 vaccination programme on symptomatic and severe SARS-CoV-2 infection during a period of Omicron variant dominance in Ireland, December 2021 to March 2023;Eurosurveillance;2024-07-11

3. Estimating All-Cause Deaths Averted in the First Two Years of the COVID-19 Vaccination Campaign in Italy;Vaccines;2024-04-13

4. Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study;Influenza and Other Respiratory Viruses;2024-04

5. Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: A review and case study;Science Advances;2023-12-22